Medical therapy for relief of symptoms of benign prostatic hyperplasia (BPH) is now a clinical reality. The challenge for urologists treating BPH with medical therapy is how to rationally employ the two proven classes of medications, the alpha blockers and ®nasteride, in their practice. To accomplish this, we must critically examine the results of multiple important clinical BPH trials published over the last decade and examine the short and long term effect of the various available medical therapies on symptoms, objective progression and consequences of the disease process and whether evidence based indicators will allow us to choose appropriate therapies. It appears that we can rationalize our medical therapy decisions, taking into consideration severity of disease, prostate size (and perhaps PSA) and most importantly, the patients' longterm expectations for treatment outcome. But ®rst physicians must decide for themselves whether to expand their treatment paradigm beyond short term symptom relief to encompass long term durability and even prevention of the consequences of the long term progression of BPH.
The challenge
During the last decade medical therapy for benign prostatic hyperplasia (BPH) has become a clinical reality. 1 Two classes of medication have emerged with consistently proven results in randomized controlled trials as better than placebo: the alpha-blockers and the 5-alphareductase inhibitors. Well designed studies have proven that these medications are both safe and effective over the short term (1 y).
The challenge for urologists treating BPH with medical therapy is how to rationally employ these medications in their practice. To tackle this task we must ask a number of fundamental questions: Is BPH a long term progressive disease? Should the solution for this disease with medical therapy be viewed not in terms of weeks, months or even a year, but rather be considered a life time treatment for the patient? As surgeons we have always been most interested in short term symptom relief. But now, should we be convinced that that therapy is safe over the long term, has long term ef®cacy compared to placebo, is durable over years and even decades, hopefully has the ability to halt the progression of the disease and prevent complications such as acute urinary retention or the requirement for surgery? The ultimate challenge is whether we as a urological community are ready to expand beyond short term symptom relief to long term symptom control and perhaps even prevention of disease progression with its associated complications.
The problem
It appears, that in many (but certainly not all) patients with lower urinary tract symptoms, BPH can indeed be considered a slowly progressive disease. The prostate gland increases in size at an average rate of 0.6 ml/y with some age variation. 2 The average decrease in¯ow rate over time, which is an indirect measure of obstruction, is about 2 ml/sec/decade. 3, 4 The frequency and severity of symptoms also progress with age, but this progression is highly variable over time and between individual patients. 5±7 Acute urinary retention occurs at an average rate of 2.5% year in patients with lower urinary tract symptoms being followed with watchful waiting. 8 Surgery results as a consequence of the progression of the disease, but the only factors that predict the necessity of surgery are age, prostate size and obstructive voiding symptoms. 9, 10 Approximately 25% of patients with moderate symptoms who chose watchful waiting eventually have surgery over a short four year period. 8 The short term answer?
Placebo controlled trials up to one year duration 11 have con®rmed that patients treated with ®nasteride demonstrate a signi®cant reduction in prostate size, improvement in uro¯ow and reduction of symptoms compared to placebo. Similar placebo controlled trials 12±14 of shorter duration have also unequivocally shown that alpha blockers also improve uro¯ow and symptoms compared to placebo. But there is no doubt that for an unselected population of men with lower urinary tract symptoms, the alpha blockers provide a quicker, more reliable and more signi®cant short term symptom relief than does ®nasteride. 15 The rationalization of medical therapy, however, comes from a critical look at the not only at the short term effects but also the side effect pro®le, long term effects, selection implications and consequence of therapy on long term associated outcomes ( Table 1 ).
The long term answer?
The results of three recent long term randomized controlled studies are available which suggest that ®nasteride may prevent further progression of the disease; the Canadian PROSPECT study 16 with 613 patients and the Scandinavian SCARP 17 study with 707 patients randomized patients with moderate BPH to either placebo or ®naster-ide for two years. Prostate volume decreased by appoximately 20% compared to an increase in in the placebo group. Mean symptom scores decreased by about two points and the maximum¯ow rate increased by about 1.5 ml/s in the ®nasteride groups after two years. There was no signi®cant change in symptoms or¯ow rate in the placebo groups. A similar world wide two year randomized controlled trial, the PROWESS study, was recently reported, 18 and the data from 3255 patients from 41 countries con®rmed the results of the PROSPECT and SCARP study.
Open extension studies of the randomized controlled trials have allowed us to follow the progress of patients who remain on medical therapy. A report of a three year open extension study 19 for the initial one year North American and International ®nasteride studies demonstrated that the bene®cial effects were maintained for that period of time. Further reports show that this improvement seen with ®nasteride on symptomatic relief and urinary¯ow rates for patients with BPH, associated with signi®cant shrinkage of the prostate gland, was subsequently sustained through ®ve years of therapy. 20 There is no evidence of an increase in adverse experiences with increased duration of therapy. There is no doubt now that the data indicates the response to ®nasteride is durable for at least ®ve years.
There is also data now available that attests to the long term ef®cacy of alpha-blockers. An open label multicenter study evaluated the long term ef®cacy and safety of terazosin 21 and con®rmed that the improvement in¯ow rates and symptom scores compared to baseline were maintained through 42 months. At the time of publication, 43% of the patients on alpha-blockers withdrew from the study prematurely (usually not from adverse reactions) and at 42 months, approximately 10% of the patients were evaluable. Long term studies with doxazosin 22 and tamsulosin 23 have also demonstrated long term ef®cacy in relieving symptoms and improving uro¯ow over four years. While these studies also suffer from a lack of mature data, in that only approximately 10% of the patients were evaluable at four years, there is no doubt that alpha blocker therapy is durable in some patients.
The magnitude of improvement in symptom score of these responder groups (it is likely only responders would continue in open label studies for up to four years) with terazosin at 42 months (and other alpha blockers at 48 months) and ®nasteride at 60 months were remarkably similar.
Does prostate size make a difference?
It is evident that medical therapy results in improvement in symptoms and¯ow rates in some patients with ®nas-teride and most patients with alpha blockers over both the short term and long term. How then does one explain the inconsistent results seen in the Veterans Administration BPH trial 15 ? In this landmark study, the ef®cacy of terazosin was con®rmed while ®nasteride was found to be marginally better than placebo. Only recently can this Table 1 The differences in action, rapidity of effect, adverse side effects, ef®cacy and durability in relation to prostate size and their effects on long term consequences of BPH will assist the physician to rationally choose the right medication for right patient employed data available from six placebo controlled trials, including the VA trial, involving 2601 men with BPH treated with ®nasteride or placebo for at least one year to determine whether prostate size could predict the outcome of ®nasteride therapy. They found that the effect of ®nasteride treatment on improvements in symptom scores and peak urinary¯ow rates were consistent and could be directly attributable to the mean prostate size seen in that individual study. The larger the average prostate gland size in each particular study, the greater and more signi®cant was the improvement in¯ow rate and symptoms seen in that particular study. A pooled data analysis of all the data from all the trials allowed symptom score and peak¯ow rate changes to be assessed according to the range of prostate size. This pooled analysis demonstrated clearly that as prostate volumes increased, so does the therapeutic response measured by symptom score and uro¯ow improvements. A signi®cant improvement of ®nasteride over placebo was noted for all men with prostate volumes of 40 ml or greater. This metaanalysis suggested that ®nasteride is most effective in men with large prostate glands and perhaps for symptom relief this medical therapy should be restricted to this patient population. Men with smaller, normal size prostate glands may not be suitable candidates for ®nasteride therapy for BPH. Recently, Roehrborn using the same data base that was employed for the meta-analysis that con®rmed prostate size was important, suggested that PSA could be used as a surrogate for prostate size. 25 It this turns out to be the case, then it may be appropriate to consider patients with a PSA over some cut-off point, probably around 2.0 ng/ml (1.5±2.5 ng/ml) as reasonable candidates for ®nasteride therapy.
Does prostate volume affect the response of alphablockers when used to treat the symptoms of BPH? There is no evidence that initial alpha-blocker ef®cacy is related to baseline prostate size. There is a paucity of longterm data at the present time, however, Brawer et al 26 recently reported that twice as many patients with small prostate glands compared to large prostate glands were evaluable in an open label terazosin trial at four years. This suggested that the long term drop out rate might be twice as high in men with large prostate glands compared to men with smaller prostate glands.
Is prostate volume related to any of the important longterm BPH endpoints? Urologic dogma teaches that in the hightly selected symptomatic patient populations referred to urologists, symptoms and¯ow rates cannot be well correlated with prostate size. Recent population based studes show that prostate volume, in unselected populations of men, is implicated in both the severity and progression of BPH compared to men with normal size prostate glands (Table 2) . Men with large prostate glands are 3.5 times more likely to have moderate or severe symptoms, 27 2.5 times more likely to have decreased ow, 27 have 3±4 times the risk of acute urinary retention over 3.5 y 28 and more likely to require surgery. 9,10 It certainly appears in population based studies (as opposed to clinical studies in selected men presenting for therapy of their BPH) that a large prostate gland does predict the severity and possibly the progression of disease.
Does medical therapy change the incidence of BPH complications?
Investigators in the SCARP study 17 noted that over a two year period, fewer patients in the ®nasteride group experienced acute urinary retention (AUR) and underwent prostate surgery compared to patients in the placebo group. This observation was the stimulus for a formal analysis which assessed the hypothesis using a pooled analysis of data from three large, fully compatible, multicenter, double-blind, placebo controlled trials representing the combined experience of 4222 men. 29 Over the two year period, 2.7% of the placebo group compared to 1.1% of the ®nasteride group suffered acute urinary retention (57% reduction in hazard rate for ®nasteride treated patients; P`0.001). Over the same period of time, 6.5% of the placebo group compared to 4.2% of the ®nasteride group underwent BPH related surgery (34% reduction in hazard rate for ®nasteride treated patients; P`0.002)
The results of the USA PLESS study, 30 the largest and longest BPH study ever completed, was ®rst reported by Dr J McConnell at the SIU meeting in Montreal in September 1997. This landmark study con®rmed the hypothesis generated by the Endpoint Analysis. In this multicenter, double blind, randomized, placebo-controlled four-year trial, 3040 men with moderate to severe symptoms of BPH and enlarged prostates were assessed for changes in symptom score,¯ow rate, prostate size (a subgroup) and more importantly for incidence of BPH-related outcomes including surgery and acute urinary retention. Over the four-year period, 10.1% of placebo vs 4.6% of ®nasteride treated patients underwent BPH-related surgery (55% reduction in risk for ®naster-ide-treated patients; P`0.001). Acute urinary retention developed in 6.7% and 2.8% of placebo-and ®nasteride-treated patients respectively (57% reduction in risk with ®nasteride; P`0.001). In this longterm placebo-controlled study, ®nasteride also produced durable improvements in symptoms of BPH, prostate volume and urinary¯ow rate. The improvements in symptoms and the reduction Table 2 Importance of prostate size in relation to long term endpoints associated with BPH In population based studies, men with large prostate glands compared to men with normal sized or small prostate glands are:
1. 3.5 times more likely to have moderate or sever symptoms 27 2. 2.5 times more likely to have decreased¯ow rate 27 3. 3 to 4 times more likely to suffer acute urinary retention 27 4. signi®cantly more likely to require surgery 9, 10 in incidence of BPH-related acute urinary retention and surgery rates were more pronounced in patients with larger prostate glands and/or PSA over 1.5 ng/ml. At this point, most studies have not demonstrated that alpha-blockers reduce similar long term endpoints. In one study comparing alfuzasin to placebo, 31 there was an indication that this particular alpha blocker may have an effect on these outcomes in the short term. However in the one-year terazosin outcomes study in 2084 men, the 1-year incidence of AUR was 1.3% in both the placebo and terazosin treated groups. 32 In a one year community based study to determine the long bene®ts of terazosin, a reduced need for surgical intervention was not demonstrated (4.7% of placebo-treated patients vs 3.9% in terazosin treated patients). 33 Is this magnitude of reduction in acute urinary retention rates and surgical rates seen in the ®nasteride endpoint and PLESS studies clinically important? Acute urinary retention is often considered by patients to be the most serious outcome of BPH 34 and many symptomatic men are electing medical therapy in the hopes of avoiding surgery. Men with lower urinary tract symptoms being followed with watchful waiting have an AUR occurrence rate of 2.5% per year. An epidemiologic calculation for estimating risk over time as a cumulative incidence 35 of Jacobson's 28 recently reported Olmsted County data demonstrates that a 60 y old man with lower urinary tract symptoms would have approximately a 23% life time risk of developing acute urinary retention. Therefore it appears obvious that to an individual man with lower urinary tract symptoms, that a medication that can reduce an ongoing risk of incidence of acute urinary retention by over 50% would be clinically important. Similarly patients with moderate symptoms of BPH on watchful waiting, have a surgical rate of almost 25% over four years. 8 A reduction in this rate by more than 50% would have signi®cant clinical and economical rami®cations.
Is it time to expand our treatment paradigm?
Alpha-blockers are effective in alleviating lower urinary tract symptoms regardless of prostate size. In many men, this effect continues up to four years, however there remains concern about the long term durability of alpha-blocker therapy, particularly in men with large prostate glands and ®nal reporting of long term studies with mature data are necessary. Men with small or normal sized prostate glands appear less likely to suffer progression, acute urinary retention or require surgery and in these patients long term alpha blockade theoretically would be the best long term option with the fewest long term adverse outcomes. On the other hand, ®naster-ide works slower to alleviate lower urinary tract symptoms by decreasing prostate gland size and appears to work most effectively in men with large prostate glands. Men with small prostates may not be suitable candidates for ®nasteride therapy. Men with large prostate glands are more likely to have more severe symptoms, decreased uro¯ow, and are more likely to develop acute urinary retention or require surgery. At this point, only ®nasteride has been shown to unequivocally reduce the incidence of acute urinary retention or surgery. It appears that we can rationalize our medical therapy decisions, taking into consideration severity of disease, prostate size (and perhaps PSA) and most importantly, the patients' longterm expectations for treatment outcome (Table 3) . But ®rst physicians must decide for themselves whether to expand their treatment paradigm beyond short term symptom relief to encompass long term durability and even prevention of the consequences of the long term progression of BPH. 
